期刊
SEMINARS IN CANCER BIOLOGY
卷 42, 期 -, 页码 44-51出版社
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.semcancer.2016.11.002
关键词
Drug resistance; Lung cancer; Precision medicine; Pharmacogenomics profile; CRISPR-Cas9 screening; Pathway-centric therapy
类别
资金
- Zhongshan Distinguished Professor Grant (XDW)
- National Nature Science Foundation of China [31571363, 91230204, 81270099, 81320108001, 81270131, 81300010]
- Shanghai Committee of Science and Technology [12JC1402200, 12431900207, 11410708600, 14431905100]
- Operation funding of Shanghai Institute of Clinical Bioinformatics
- Ministry of Education, Academic Special Science and Research Foundation [20130071110043]
Targeted therapies are suggested as an effective alternative for patients with cancer that harbor mutations, but treatment outcomes are frequently limited by primary or acquired drug resistance. The present review describes potential mechanisms of primary or acquired drug resistances to provide a resource for considering how to be overcome. We focus on strategies of targeted drug combinations to minimize the development of drug resistance within the context how resistance develops. Strategies benefit from the combined use of omics technologies, i.e., high-throughput functional genomics data, pharmacogenomics, or genome-wide CRISPR-Cas9 screening, to analyze and design targeted drug combinations for mutation-driven drug resistance. We also introduce new insights towards pathway-centric combined therapies as an alternative to overcome the heterogeneity and benefit patient prognoses. (C) 2016 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据